__________________________________________________________________________________ OXB( Oxford Biomedica)
working. We want our different vectors to be implemented across the organization so that our clients have complete flexibility to choose where they would like their products to be manufactured,” Mark reveals, optimistic for OXB’ s future ahead.“ In the next five years, I see the company being the world-leading viral vector CDMO, and we are now very well positioned to capitalize on the wave of expected cell and gene therapy approvals, with our scalable, state-of-the-art facilities that will allow us to continue to expand across our sites and meet growing client demands. Having a dedicated team that focuses on nothing but innovation speaks to our commitment to deliver best-in-class solutions to our clients, and we strive to stay at the pinnacle of the market as we move into the future.”
As OXB moves forward to build upon its existing legacy, Mark takes a moment to home in on OXB’ s greatest asset: its incredible team.
“ One of the key driving forces behind our success is the values that we live everyday: Responsible, Responsive, Resilient, and Respect,” he affirms.“ Earlier in 2025, I had the opportunity to receive the 2025 CDMO Leadership Award as the top cell and gene therapy CDMO in Europe. We were selected based on the number of votes that we received from across the industry – what better way to say that you’ re one of the best in the industry than receiving an unbiased award like that.
“ We have phenomenal people here at OXB. At the end of the day, every company can have the same equipment that we have, but it’ s truly the people who stand out,” Mark concludes.“ They work day-in and day-out to deliver these life changing therapies to our clients in support of their patients; they are the true heroes of what we do.” ■
www. oxb. com
manufacturing-today. com 49